英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

operand    
运算对象,操作数

运算对象,操作数

operand
运算元; 运算元的; 运算数; 操作数; 运算对象 OP; OPND

operand
运算元

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • GATA6 Expression Distinguishes Classical and Basal-like Subtypes in . . .
    AbstractPurpose: To determine the impact of basal-like and classical subtypes in advanced pancreatic ductal adenocarcinoma (PDAC) and to explore GATA6 expression as a surrogate biomarker Experimental Design: Within the COMPASS trial, patients proceeding to chemotherapy for advanced PDAC undergo tumor biopsy for RNA-sequencing (RNA-seq) Overall response rate (ORR) and overall survival (OS
  • GATA6 expression distinguishes classical and basal-like subtypes in . . .
    This is a pre-copyedited, author-produced version of an article accepted for publication in Clinical Cancer Research following peer review The version of record "GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer "
  • Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer . . .
    The best progression-free survival was observed in those with classical subtype treated with m-FOLFIRINOX GATA6 expression in tumor measured by RNA in situ hybridization was found to be a robust surrogate biomarker for differentiating classical and basal-like PDAC subtypes Potentially actionable genetic alterations were found in 30% of patients
  • GATA6 Expression Distinguishes Classical and Basal-like Subtypes in . . .
    To determine the impact of basal-like and classical subtypes in advanced pancreatic ductal adenocarcinoma (PDAC) and to explore GATA6 expression as a surrogate biomarker Within the COMPASS trial, patients proceeding to chemotherapy for advanced PDAC undergo tumor biopsy for RNA-sequencing (RNA-seq) Overall response rate (ORR) and overall survival (OS) were stratified by subtypes and
  • GATA6 expression distinguishes classical and basal-like subtypes in . . .
    PURPOSE: To determine the impact of basal-like and classical subtypes in advanced PDAC and to explore GATA6 expression as a surrogate biomarker EXPERIMENTAL DESIGN: Within the COMPASS trial patients proceeding to chemotherapy for advanced PDAC undergo tumour biopsy for RNA sequencing
  • Data from GATA6 Expression Distinguishes Classical and Basal-like . . .
    AbstractPurpose:To determine the impact of basal-like and classical subtypes in advanced pancreatic ductal adenocarcinoma (PDAC) and to explore GATA6 expression as a surrogate biomarker Experimental Design:Within the COMPASS trial, patients proceeding to chemotherapy for advanced PDAC undergo tumor biopsy for RNA-sequencing (RNA-seq) Overall response rate (ORR) and overall survival (OS) were
  • GATA6 expression in advanced pancreatic ductal adenocarcinoma (PDAC) as . . .
    GATA6 expression, a transcription factor identifies the classical phenotype and is associated with superior overall survival (OS), low GATA6 predicts a basal-like phenotype, associated with a poorer prognosis
  • GATA6 identifies an immune-enriched phenotype linked to favorable . . .
    This study underscores GATA6’s role in distinguishing classical and basal-like pancreatic ductal adenocarcinoma (PDAC) phenotypes Retrospective studies associate GATA6 immunohistochemistry (IHC) expression with survival outcomes, warranting prospective validation In a prospective treatment-naive cohort of patients with resected PDAC, GATA6 IHC proves a prognostic discriminator, associating
  • Article - GATA6 Expression Distinguishes Classical and Basal-like . . .
    PURPOSETo determine the impact of basal-like and classical subtypes in advanced pancreatic ductal adenocarcinoma (PDAC) and to explore GATA6 expression as a surrogate biomarker EXPERIMENTAL DESIGNWithin the COMPASS trial, patients proceeding
  • Checking your browser - reCAPTCHA - PubMed
    Checking your browser before accessing pubmed ncbi nlm nih gov
  • Whole genome and transcriptome profiling in advanced pancreatic cancer . . .
    The COMPASS trial is a prospective observational study seeking to establish biomarkers in advanced pancreatic cancer through in-depth profiling prior to commencing chemotherapy





中文字典-英文字典  2005-2009